secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001104659-23-113589
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q3 revenue $1.52B, adj. EPS $0.87; narrows & lowers FY2023 guidance
---------------------------------------------------------------------------

- Revenue $1,519M (-1% YoY); diluted EPS $0.23; non-GAAP adj. diluted EPS $0.87.
- Women's Health -7% ex-FX; Biosimilars +10% ex-FX; Established Brands +3% ex-FX.
- Board declares quarterly dividend $0.28 per share, unchanged.
- FY2023 revenue guidance narrowed to $6.15-6.25B (prev. $6.15-6.35B); adj. EBITDA margin 30.5-31.5% (prev. 31-33%).
- Adjusted EBITDA $447M, margin 29.4% vs 35.5% a year ago.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465923113589/0001104659-23-113589-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465923113589/tm2329655d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113589

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer